-- Scott Roberts
THURSDAY, Aug. 7, 2014 (HealthDay News) -- The antibacterial
drug Orbactiv (oritavancin) has been approved by the U.S. Food and
Drug Administration to treat drug-resistant skin infections in
adults, the agency said in a news release.
The drug is sanctioned to treat methicillin-resistant
Staphylococcus aureus(MRSA) and other acute bacterial skin
infections. It's the third such drug approved in 2014, following
May approval of Dalvance (dalbavancin) and June approval of
Sivextro (tedizolid), the FDA said.
Orbactiv's safety and effectiveness were evaluated in two
clinical studies involving almost 2,000 adults. The most common
side effects included headache, nausea, vomiting, skin abscesses on
the arms and legs, and diarrhea.
The drug's label will include a boxed warning that it could
interact with the blood-thinning medication warfarin, the agency
Orbactiv is marketed by The Medicines Company, based in
The FDA has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.